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Abstract
Background: The role of copy number variation of the CCL3L1 gene, encoding MIP1α, in contributing to the host
variation in susceptibility and response to HIV infection is controversial. Here we analyse a sub-Saharan African co-
hort from Tanzania and Ethiopia, two countries with a high prevalence of HIV-1 and a high co-morbidity of HIV with
tuberculosis.
Methods: We use a form of quantitative PCR called the paralogue ratio test to determine CCL3L1 gene copy
number in 1134 individuals and validate our copy number typing using array comparative genomic hybridisation
and fiber-FISH.
Results: We find no significant association of CCL3L1 gene copy number with HIV load in antiretroviral-naïve pa-
tients prior to initiation of combination highly active anti-retroviral therapy. However, we find a significant associ-
ation of low CCL3L1 gene copy number with improved immune reconstitution following initiation of highly active
anti-retroviral therapy (p = 0.012), replicating a previous study.
Conclusions: Our work supports a role for CCL3L1 copy number in immune reconstitution following antiretroviral
therapy in HIV, and suggests that the MIP1α -CCR5 axis might be targeted to aid immune reconstitution.
Background
AIDS, caused by the retrovirus HIV, is predicted by 2030
to become globally the single largest cause of morbidity,
as measured by disability-adjusted life-years [1]. African
countries currently have the highest disease burden of
HIV, with 9.2% prevalence in Addis Ababa in Ethiopia
and over 10% in Dar-es-Salaam in Tanzania, yet almost
all genetic studies have focused on cohorts from
Western countries [2]. The genetic architecture of HIV
susceptibility in Africans is likely to be different to
Europeans, yet genome-wide association studies of host
susceptibility to HIV have not yielded any significant re-
sults [3]. These studies miss regions that show copy
number variation, particularly structurally complex
regions that are not correlated with alleles at flanking
SNP markers [4].
Copy number variation (CNV) is defined as the vari-
ation in copy number of a given DNA sequence in a dip-
loid genome. CNV is common in the genome, affects
gene expression, and involves immune response genes
[5-7], suggesting that it may affect susceptibility of the
host to infectious disease. CNV of the killer cell im-
munoglobulin receptor genes has been shown to affect
host control of HIV infection, as determined by the viral
load (VL) at setpoint [8], and we have recently shown as-
sociation of β-defensin CNV both with HIV viral load at
initiation of highly-active anti-retroviral therapy (HAART)
and with consequent immune reconstitution [9].
The genes CCL3L1/CCL4L1 encode the chemokines
MIP-1α and MIP-1β which are both ligands for the che-
mokine receptor CCR5 used as a co-receptor by R5
strains of HIV. These genes show CNV, and this has
been shown to affect HIV acquisition, progression to
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AIDS, and immune reconstitution following highly ac-
tive anti-retroviral therapy (HAART) [10-12]. An attract-
ive model is that these chemokines and HIV compete for
the same receptor CCR5, and that increasing copy num-
ber increases the levels of chemokine, thereby increasing
competition with HIV for the receptor [13]. A gene dos-
age effect linking gene copy number and protein levels is
needed to support this hypothesis, and evidence has
been contradictory. Early studies supported a gene dos-
age effect [10,11], but recent studies have suggested that
the influence of extra gene copies on total protein levels
is low [14,15]. A problem in these experiments is that
the protein product of CCL3 (called MIP1α-LD78α) and
CCL3L1 (MIP1α-LD78β) cannot be discriminated using
standard antibodies. Thus analyses using antibody-based
detection of protein products may not detect a gene dos-
age effect, particularly given the higher levels of CCL3
transcription and presumably MIP1α-LD78α in the
blood. Although both protein isoforms signal through
CCR5, only the LD78β isoform can be cleaved by dipetidyl
peptidase IV to generate a monocyte attractant and CCR1
agonist [16,17]. Indeed, functional evidence remains sup-
portive: measuring the chemotactic response of cells to
supernatants from lipopolysaccharide-stimulated mono-
cytes from different individuals supports an effect of
different CCL3L1 gene copy number [10]. However, other
mechanisms for an effect of CCL3L1 copy number can be
invisaged, either directly or indirectly by affecting other im-
munological phenotypes such as the CD4+ cell count.
Attempts at replicating the genetic association of CCL3L1
copy number and HIV susceptibility have yielded contrast-
ing results. A meta-analysis of nine studies has supported
an association of lower CCL3L1 with susceptibility to HIV
[18], but this study did not critically analyse the quality of
the published data used in the meta-analysis. For example,
the use of quantitative PCR to determine CCL3L1 copy
number may generate false-positive associations [19-21]. It
may be that CCL3L1 and CCL4L1 do not always vary in
copy number as a block, which might explain at least some
of the heterogeneity in results when different methods are
used to determine copy number. However, when more ro-
bust reliable methods are applied to large European cohorts
there is no evidence of this, suggesting that when measured
with sufficient precision and accuracy, CCL3L1 and
CCL4L1 covary as a block [22,23]. In common with most
of the literature, we refer to this copy number variation as
CCL3L1 copy number variation, but it should be remem-
bered that it also involves CCL4L1 and possibly TBC1D3.
CCL3L1 CNV has also been associated with a variety
of other infectious diseases, including tuberculosis [24],
hepatitis B [25], hepatitis C [26] and Kawasaki Disease
[27]. Such association studies are almost always small,
use qPCR to type copy number, not necessarily repli-
cated [28], and in some cases the reported association is
seen only on a background of a particular genotype at
another locus. While such studies are based on reason-
able hypotheses concerning the function and interaction
of proteins and pathogens, the marginal significance
levels and limited power of such studies means that
drawing definitive conclusions regarding the role of gen-
etic variation remains difficult. In the most technically- and
genetically-thorough study to date, a weak suggestive asso-
ciation with protection from anemia in malarial infection
was found, but this family-based study too lacked power to
detect anything but strong effects [29].
Evidence from other African studies of CCL3L1 and
HIV has been contradictory. In a small Zimbabwean
longitudinal cohort, no association of CCL3L1 copy
number with HIV status or progression was found [30].
However, analysis of mother-to-child transmission in
South Africa suggested that higher copy number was
protective against HIV transmission [31]. In this context,
we decided to analyse our previously described cohort of
HIV patients from Ethiopia and Tanzania for association
of CCL3L1 copy number with viral load immediately
prior to HAART and immune reconstitution during
HAART. African populations are known to have a
higher average copy number than European populations
[11,31], due either to natural selection or genetic drift.
This has the advantage, in an association study context,
of providing a wider range of copy number and therefore
a potentially larger gene dosage effect. However, there
are significant technical challenges in accurately typing
multiallelic copy numbers at this, or indeed other, loci.
We decided to use the paralogue ratio test (PRT) to deter-
mine copy number, which is the most robust technique
available for typing this locus on large cohorts [19,21].
Methods
Sample collection
Patient sample, DNA extraction and clinical data collec-
tion was as previously described [9,32,33]. The study
protocol was approved by the Institutional Review Board
at the Faculty of Medicine, Addis Ababa University and
Ethiopian Science and Technology Ministry; the regional
ethical review board in Stockholm at the Karolinska
Institutet and the ethical review committee of Muhimbili
University of Health and Allied Sciences. Written in-
formed consent was obtained from each subject before
the start of this study. DNA samples from the HapMap
YRI population (Yoruba from Ibadan, Nigeria) were
obtained from Coriell Cell Repositories (Camden, NJ,
USA).
The CCR5 δ32 allele, associated with protection from
HIV infection and disease, progression, was not detected
in either the Tanzanian or Ethiopian samples [9], where
the deletion allele is known to be protective against HIV
progression. Patient numbers used at each stage of the
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study are given in Additional file 1: Table S1. Baseline char-
acteristics of patients are given in Additional file 2: Table S2.
Copy number typing
Copy number typing was performed using the PRT ap-
proach described previously [22]. Briefly, data from three
separate PRT assays measuring copy number across the
CCL3L1 segmental duplication are normalised using
four known positive control samples (C0075 – 1 copy,
C0150 – 2 copies, C0007 – 3 copies, C0877 – 4 copies),
available as part of the human reference control plate
HRC-1 from the Health Protection Agency, Porton, UK,
analysed with every experimental PCR plate, and then
averaged to give an unrounded estimate of copy number.
The replicate testing of the four positive controls using
the three separate PRT assays produces datapoints that
clearly cluster, with clusters showing a linear relationship
with copy number, and no assay-specific biases in
clustering (Additional file 3: Figure S1).
Samples were tested in duplicate if the coefficient of
variation of the values from the three separate assays
exceeded a given threshold, typically 0.2, and the result
that gave the lower coefficient of variation taken on to
the next stage of analysis. A small number of samples
gave consistently high (>0.5) coefficient of variation
scores even after repeated testing. This was due to al-
tered copy number of either LTR16 or CCL4, and for
these the copy number from the two consensus PRTs
was taken forward. However, in general, raw copy num-
ber estimates from each of the three PRT assays was
highly concordant across samples, with clustering about
integer copy numbers evident at lower copy numbers
(Additional file: 4 Figure S2).
Integer copy numbers were inferred from mean un-
rounded copy number estimates using a Gaussian mix-
ture model, implemented in the statistical language R
(package CNVtools [34]). The appropriateness of using
Gaussian distributions to model PRT data can be tested
by analysis of the data from the positive control samples
analysed on every PCR plate. When normalised by copy
number, it is clear that the combined dataset fit the
Gaussian distribution well, although a number of out-
liers are seen (Additional file 5: Figure S3a). These out-
liers seem to be more likely for the lower copy number
samples, suggesting that the assumption of the Gaussian
distribution not only holds but may even be a stronger
assumption for PRTs measuring higher copy numbers
(Additional file 5: Figure S3b). A mixture model of nine
components was fitted, based on observation of the data
and prior studies. The model of variance components
was fixed to have similar variance, an assumption sup-
ported by the similar variance of the repeated PRT
values from the four positive controls. The resulting
clustering quality score (Q) was 3.9. A posterior
probability of the integer copy number call being correct
was given for each sample. Where this probability was
below 0.8, and the probability of the copy number one
higher or one lower was therefore >0.2, then the mean
of a duplicate test (if carried out) was used to call the
correct integer copy number.
Fibre FISH
Fibre-FISH was performed as described previously
[35]. Briefly, stretched DNA fibers were prepared from
lymphoblastoid cell lines. Fosmid DNA was prepared
using the Phase-Prep BAC DNA kit (Sigma-Aldrich)
following the manufacturer’s protocol. Fosmids used
were G248P85689G4 (white, hg18 chr17:31434865–
31475400), G248P84883A8 (green, hg18 chr17:3146
8941–31505286) and G248P8961D8 (red, maps to
hg18 twice at chr17:31537181–31574736 and chr17:3
1638770–31676303). The green clone was labelled with
Dinitrophenol (DNP)-11-dUTP (PerkinElmer) and de-
tected with rabbit anti-DNP and Alexa 488 conjugated
goat anti-rabbit IgG. The red clone was labelled with
Digoxigenin (DIG)-11-dUTP (Roche) and detected
with monoclonal mouse anti-DIG IgG (Sigma-Aldrich)
and Texas red conjugated donkey anti-mouse IgG
(Invitrogen). The white clone was labelled with biotin-
16-dUTP and detected with one layer Cy3-avidin. After
detection, slides were mounted with SlowFade Gold®
(Invitrogen) mounting solution containing 4′, 6-diami-
dino-2-phenylindole (Invitrogen). Images were cap-
tured on a Zeiss Axioplan fluorescent microscope and
processed with the SmartCapture software (Digital
Scientific UK).
Statistical analysis
To analyse the effect of CCL3L1 on HIV load at initi-
ation of HAART, we initially constructed a generalised
linear model using SPSS 20.0 (IBM) and a gamma-
identity link, as previously published. This link function
did not model the data (which included new clinical
data) well, and a gamma-log link provided a better fit to
the data. Notably, for the previously-published β-
defensin dataset [9], both gamma-identity and gamma-
log links model the data well, and although the gamma-
identity model was chosen, the two models are almost
indistinguishable based on several goodness-of-fit cri-
teria and report very similar significance levels, therefore
not calling our previous results into question. The model
was calculated using type III sum of squares ANOVA,
with goodness-of-fit analysed using Wald statistics.To
examine the effect of CCL3L1 copy number on CD4+
count following initiation of HAART, we constructed a
generalised linear mixed model, using STATA, where the
dependent variable (CD4+ count) was modelled as a
Gaussian distribution. In this model, we assigned
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population and disease status as fixed factors, initial
CD4+ count and time since HAART initiation as scalar
covariates and integer copy number as an ordinal covari-
ate. The model was calculated using type III sum of
squares ANOVA, with a variance correction to allow for
multiple CD4+ timepoint readings from a single patient.
Results
Analysis and validation of copy number typing
We used a previously-published and well-established
method for copy number typing, called the paralogue ra-
tio test (PRT) to type CCL3L1 copy number (Figure 1a).
1134 samples were tested in total, and integer copy
number called using a Gaussian mixture model ap-
proach (Figure 2, see Methods) after removal of one out-
lier with very high copy number (~14). 192 (16.9%)
samples gave an integer copy number call posterior
probability of less than 0.8. Of these, 57 (30%) had been
tested in duplicate, of these 57 duplicates, 34 (60%) sup-
ported the original copy number call and 23 supported
the alternative copy number call (Additional 6: Figure
S4). If we conservatively assume that there is no correl-
ation between the samples selected for duplicate testing
because of high coefficient of variation values and the
samples giving posterior probability values <0.8, we can
estimate the error rate to be 6.7%, and these errors will
involve an incorrect call of +/- 1 copy number. Error
rate is likely to be significantly lower than this because
samples were selected for duplicate testing based on
high coefficient of variation values, and are therefore
likely to be significantly enriched for miscalled samples.
To validate our copy number calling at higher copy
numbers, we used fibre-FISH on extended DNA fibres
from cell lines derived from a parent–child trio from the
YRI HapMap population. Our estimates, estimated from
PRT prior to fibre-FISH analysis, agreed with the num-
ber of copies determined by FISH (Figure 1b). This is
shown by the fosmid probe labelled red, which maps to
the CCL3L1 repeat and has been used previously to esti-
mate copy number in humans [35]. Interestingly, of the
14 CCL3L1 repeats directly visualised in these three
trios, 11 have a repeat structure that includes a fosmid
probe, labelled in green, which covers a region between
the CCL4 gene and the TBC1D3 and CCL3L1 genes.
This is in contrast to CCL3L1 repeats previously visua-
lised in Europeans, where the repeat appears to be rep-
resented just by the red-labelled probe, and has been
estimated to be 90 kb in size. Therefore, in Yoruba at
least, and perhaps in other sub-Saharan Africans, there
appears to be heterogeneity in CCL3L1 repeat structure
not yet observed in Europeans.
Concordance of the three PRT assays is an important
test of heterogeneity of the repeat. Studies of CCL3L1/
CCL4L1 copy number in European populations using
the PRT method by us (unpublished data) and others
[23] have shown concordance between all three probes,
supporting the idea that this region is copy number vari-
able en bloc and averaging the values of the three probes
accurately reflects the copy number of this block.
However, in this study, a small number of Ethiopian
samples gave consistently high coefficient of variation
scores due to one probe repeatedly giving discordant
results. These can be seen as outliers on Additional
file 4: Figure S2, and example data from samples are
given in Additional file 7: Figure S5. This suggests
either sub-Saharan African-specific copy number het-
erogeneity or rare duplication of the PRT reference
locus, and is likely to contribute to the error rate ob-
served in these data. All three PRT assays map to the
region represented by the red fosmid probe in fibre-
FISH, and this PRT heterogeneity was not observed in
the YRI or Tanzanian samples, strongly suggesting that
this heterogeneity is of a different nature to that ob-
served by fiber-FISH, and is perhaps confined to the
Ethiopian population.
To further validate our CCL3L1 copy number calls,
for the YRI HapMap samples we compared our esti-
mates with arrayCGH data previously generated using
the Agilent 210 K CNV chip [6]. There is a clear
positive correlation between the two methods, and it is
also clear that the PRT generates data that clusters
effectively into integer copy numbers, particularly
at lower copy numbers, in contrast to aCGH where
there is considerable overlap of copy number classes
(Figure 1c).
CCL3L1 copy number distribution in different populations
The copy number distributions are shown in Table 1.
As has been observed previously, the copy number
range for all three African populations is higher
than European populations, where the common copy
number range is between 1 and 4 copies per diploid
genome [22]. Of the three African populations, the YRI
show the highest mean copy number, although the
Ethiopian population shows the greatest range (be-
tween 0–8 copies) and one Tanzanian shows a particu-
larly high copy number of 14.
There is a small but marginally significant difference
(p = 0.02, t-test) between the mean copy number of the
Ethiopian HIV-only and the HIV-TB co-infected co-
hort, although this is not replicated in the smaller Tan-
zanian cohort (p = 0.69). Indeed analysis by combining
CNV calling and association testing using CNVtools,
which can account for differential bias effects between
cohorts, reported a non-significant effect for the
Ethiopian dataset (p = 0.52), suggesting a very subtle
technical bias between the DNA plates containing
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HIV-only samples and those containing HIV-TB
samples.
Association of copy number with clinical parameters
To investigate the effect of CCL3L1 copy number on
viral load, immediately prior to HAART, we fitted a gen-
eralised linear model to the data, with population of
origin, tuberculoisis co-infection status and CD4+ count
immediately prior to HAART as cofactors. We found
significant association with population of origin, TB in-
fection and CD4+ count, but no effect of CCL3L1 copy
number (Table 2). We repeated the analysis using raw
copy number values, with no change.
To investigate the effect of CCL3L1 copy number on
immune reconstitution following HAART, we measured
CD4+ count at 12, 24, 36 and 48 week intervals follow-
ing initiation of treatment. Using a multivariate linear
mixed effects model to control for the multiple repeated
measurements contributed by the same patient at differ-
ent timepoints, we found a significant association of
time since initiation of treatment, CD4+ levels at initi-
ation of treatment, population of origin, TB co-infection
status and CCL3L1 copy number (p = 0.012, Table 3,
Figure 3). The direction of effect of CCL3L1 copy
number, with higher copy number associated with
poorer immune reconstitution, agrees with previous
studies [12].
Discussion
It has been observed previously that, despite HAART being
effective at reducing HIV load to below measurable levels,
CD4+ cell count does not always return to healthy levels
[36]. This might be due to a variety of factors, including
host genetics and co-infection status. Indeed, we demon-
strate in this study (Table 3) that both initial baseline CD4+
cell count and absence of TB have a positive effect on the
CD4+ count following initiation of HAART, a commonly
used measure of immune reconstitution. The role of host
genetic variation in influencing different rates of immune
reconstitution during HAART is not well understood, yet is
of increasing importance as HAART programmes are
initiated and continued in areas of high HIV prevalence.
Several candidate genes have been suggested to play a role,
including a haplotype of the TRAIL gene and copy number
variation of the β-defensin genes [9,37]. This study suggests
that CCL3L1 copy number has a stronger effect on immune
reconstitution than β-defensins (β-defensin β = −3.63
CD4 + cells/ml per copy, CCL3L1 β = −4.75 CD4+ cells/ml
Figure 2 Calling integer CCL3L1 copy number from raw PRT data. The histogram shows the copy number distribution of 1133 individuals. A
Gaussian mixture model, with seven components, is fitted to the data, and each individual component is plotted with the corresponding integer
copy number shown above each peak.
(See figure on previous page.)
Figure 1 Validation of CNV using array CGH and fibre-FISH. a) The reference genomic region studied, showing the location of the
sequences used in the paralogue ratio test (PRT) and the fosmids used for fibre-FISH analysis. b) Fibre-FISH analysis on stretched DNA fibres
from three lymphoblastoid cell lines using the fosmid probes shown in part a). The three cell lines are from a YRI parent–child trio recruited
for the HapMap project, with their DNA sample IDs given. PRT copy number estimates are given under each ID, and copy number estimated
from each stretched individual chromosome given immediately to the left of a representative fiber-FISH image. c) Comparison of raw PRT
estimates of CCL3L1 copy number on HapMap YRI samples (x-axis) with estimates from arrayCGH data (y-axis). Points are coloured according
to final integer copy number estimates, as indicated by the key below the scatterplot. PC1=first principal component of arrayCGH data.
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per copy). However, unlike β-defensin copy number, we
find no effect of CCL3L1 copy number on viral load during
acute HIV infection, just prior to initiation of HAART.
Previous studies have used combined data from
different ethnic groups, with very different CCL3L1
copy numbers, with HAART started at different CD4
count thresholds. It might be argued that variation in
ethnicity was a confounding factor, so that ethnicity ra-
ther than CCL3L1 copy number per se, was responsible
for the variation in immunological reconstitution.
While in no way a genetically homogeneous cohort, a
fact that we attempt to account for in part by using
country of origin as a cofactor in our analyses, our
study does not combine two dichotomous ethnic
groups with very different CCL3L1 copy number
counts and different levels of access to healthcare [12].
Our entire cohort is also completely naïve to antiretro-
viral therapy prior to initiation of HAART, unlike those
previously studied [12,38].
Although we have taken care to ensure the optimum
quality of our copy number typing, problems remain
particularly in distinguishing higher copy numbers,
which are frequent in sub-Saharan African popula-
tions. Part of this is technical, due to inherent noise
in the assays used, and part biological, due to the
variation in repeat structure apparent in certain popu-
lations. Both issues cannot be resolved easily without
more extensive work on the nature and extent of struc-
tural variation at this locus in different populations,
and we suggest that this should be a prerequisite
before a comprehensive analysis of the clinical role of
CCL3L1 copy number can be made. The Genome Ref-
erence Consortium has assembled a reference allele
from sequencing BACs from a genomic library derived
from a hydatidaform mole, which contains one copy of
the CCL3L1 and CCL4L1 genes and is likely to repre-
sent the most common allele in Europeans (accession
number GL383560.1). However we show here that the
high-copy alleles characteristic of African populations
are not necessarily simply related to the European
alleles, and there is clearly a need for accessible phys-
ical remapping approaches that can be applied to a
Table 2 Model fitting – output viral load
Model β coefficient (95% CI)
(copies/mL)
P value
Population −0.67 (−0.97, -0.36) <0.001
No TB Co-infection −0.42 (−0.69, -0.16) 0.002
CD4+ count (cells/mm3) −0.003 (−0.006, -0.001) 0.008
CCL3L1 copy number −0.068 (−1.45, 0.009) 0.084
(n = 656 observations).
Table 3 Model fitting – output CD4 count after HAART
Model β coefficient (95% CI)
(cells/mm3)
P value
Time after HAART (weeks) 2.61 (2.37,2.85) <0.001
Baseline CD4+ (cells/mm3) 0.88 (0.77,1.00) <0.001
Population 19.36 (5.08,33.63) 0.008
No TB co-infection 16.64 (3.33,29.95) 0.014
CCL3L1 copy number −4.75 (−8.46, -1.05) 0.012
N = 1692 observations on 491 patients, mixed effects model accounting for
repeat measures at different timepoints.
Table 1 CCL3L1 Copy number distribution and comparisons between populations
CCL3L1 copy number Tanzanian HIV Tanzanian HIV + TB Ethiopian HIV Ethiopian HIV + TB YRI unrelated
0 0 0 0 0 7 0.03 11 0.03 0 0
1 2 0.01 2 0.01 40 0.17 46 0.14 7 0.12
2 25 0.12 13 0.09 39 0.17 71 0.22 8 0.14
3 52 0.25 40 0.28 41 0.17 86 0.26 13 0.22
4 56 0.27 48 0.33 42 0.18 55 0.17 10 0.17
5 43 0.21 22 0.15 33 0.14 35 0.11 9 0.16
6 22 0.11 15 0.10 21 0.09 17 0.05 8 0.14
7 4 0.02 5 0.03 8 0.03 5 0.02 3 0.05
8 1 0 0 0 4 0.02 0 0 0 0
9 0 0 0 0 0 0 0 0 0 0
10 0 0 0 0 0 0 0 0 0 0
14 1 0 0 0 0 0 0 0 0 0
N 206 145 235 326 58
mean 4.024 3.966 3.353 3.000 4.72
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significant number of samples to fully characterise
structural variation at this locus.
There are three other caveats in interpretation of our
study. Firstly, although we control for co-infection with
tuberculosis, which represents the major co-morbidity in
these populations, we cannot rule out that the effect of
CCL3L1 copy number is indirect, via another infection,
rather directly on immune reconstitution. Secondly, as
stated previously, the copy number variation involves
the genes for the chemokine CCL4L1, and TBC1D3, a
protein involved in macropinocytosis [39]. Although
CCL3L1 is the favoured candidate for mediating the
effect of copy number based on the known functional
role of the chemokine, a role for the other gene
products should not be completely ruled out. Thirdly,
we also cannot rule out an indirect effect of CCL3L1
copy number mediated by an effect on CD4+ levels
immediately after seroconversion, which have been
shown to affect immune reconstitution [40].
Conclusions
Taken together, our data support a role for CCL3L1
copy number in the immune reconstitution following
initiation of HAART to treat HIV infection. These data
also support the suggestion that treatment of HIV
using MIP1α analogues as part of a combined HIV
treatment regimen, might adversely affect immune re-
constitution, but a small molecule that interferes with
MIP1α interactions with cognate receptors might aid
immune reconstitution.
Additional files
Additional file 1: Table S1. Sample sizes used in the study. Arm 3 was
recruited with CD4 > 200 and TB, had CCL3L1 copy number for 96
patients called but was not matched to clinical data for this study.
Additional file 2: Table S2. Baseline characteristics of patients analysed.
Additional file 3: Figure S1. Analysis of PRT measurement noise in
control samples. Individual unrounded PRT values are plotted on the y-
axis, according to the different copy numbers of the four controls (x-axis).
Each point is coloured according which of the three different PRT assays
generated it, all three assays measuring CCL3L1 copy number.
Additional file 4: Figure S2. Clustering of PRT raw data between different
assays. For the complete dataset (n = 1133), density scatterplots were draw
comparing each of the three different assays with each other. Axis labels
indicate raw PRT values, and the colour bar on the left indicates the density of
individual datapoints. One extreme point has been omitted.
Additional file 5: Figure S3. Analysis of the distribution of PRT values
about a single copy number. a). The density of raw unrounded PRT values
of the control samples, shown in supplementary Figure 1, is plotted, with
values normalised to centre on a mean of zero. The red dotted line represents
a Gaussian distribution with a mean and standard deviation taken from the
PRT data. The blue dashed line represents a Gaussian distribution fitted to the
PRT data. b). Gaussian quantile-quantile plot of raw unrounded PRT values of
the control samples. Each value is plotted according the copy number of the
control sample, as shown in the legend. The straight line is plotted through
the first and third quantiles.
Additional file 6: Figure S4. Confidence of integer copy number calls
from raw PRT data.Raw PRT calls of the entire dataset (average of three
PRT assays) are plotted on the x-axis with posterior probability of the
resulting integer copy number call on the y-axis. Points plotted as red tri-
angles are those where P < 0.8 with a repeat measurement which gave a
different estimate of integer copy number (±1). Points plotted as green
crosses are those where P < 0.8 with a repeat measurement which gave
the same estimate of integer copy number.
Additional file 7: Figure S5. Examples of assay heterogeneity. Six
Ethiopian samples are highlighted, together with the raw PRT ratios,
coloured by PRT assay, after several repeat tests.
Figure 3 Response to HAART in Ethiopians and Tanzanians stratified by CCL3L1 copy number. Average values (solid line) and
standard error of the mean (dashed line) of CD4+ cell counts was calculated for the different timepoints following initiation of HAART.
Patients were stratified according to CCL3L1 copy number, with high copy number being greater than the median integer value, which was
3 copies in Ethiopians and 4 copies in Tanzanians. N = 798 CD4+ values in Ethiopians, n = 894 CD4+ values in Tanzanians.
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